7-Ethylamino-4-trifluoromethyl-2(1H)-quinolinone | 328953-29-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-Ethylamino-4-trifluoromethyl-2(1H)-quinolinone
• 英文别名: 7-(ethylamino)-4-(trifluoromethyl)-1H-quinolin-2-one
• CAS: 328953-29-3
• 化学式: C₁₂H₁₁F₃N₂O
• 分子量: 256.227
• InChiKey: IRACJWZGMABLEC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  7-Ethylamino-4-trifluoromethyl-2(1H)-quinolinone 、 乙醛 在 sodium cyanoborohydride 、 溶剂黄146 作用下， 反应 15.0h， 生成 7-(diethylamino)-4-(trifluoromethyl)quinoline-2(1H)-one
  参考文献：
  名称：

  Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones

  摘要：

  A series of alkylamino-2-quinolin one compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.007
• 作为产物：
  描述：

  N-(3-aminophenyl)-4,4,4-trifluoro-3-oxobutanamide 在 sodium cyanoborohydride 、 对甲苯磺酸 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 23.0h， 生成 7-Ethylamino-4-trifluoromethyl-2(1H)-quinolinone
  参考文献：
  名称：

  Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones

  摘要：

  A series of alkylamino-2-quinolin one compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.007

文献信息

• Bicyclic androgen and progesterone receptor modulator compounds and methods
  申请人：Zhi Lin

  公开号：US20050288350A1

  公开（公告）日：2005-12-29

  The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by AR and PR. More particularly, the invention relates to nonsteroidal compounds and compositions that are high affinity, high specificity agonists, partial agonists (i.e., partial activators and/or tissue-specific activators) and antagonists for AR and PR. Also provided are methods of making such compounds and pharmaceutical compositions, as well as critical intermediates used in their synthesis.

  本发明涉及化合物、制药组合物和调节由AR和PR介导的过程的方法。更具体地，本发明涉及非甾体化合物和组合物，它们是高亲和力、高特异性的AR和PR激动剂、部分激动剂（即部分激活剂和/或组织特异性激活剂）和拮抗剂。还提供了制备这些化合物和制药组合物的方法，以及在它们的合成中使用的关键中间体。
• PHARMACEUTICAL COMPOSITION FOR INHIBITING ACCUMULATION OF AMYLOID- BETA PROTEIN
  申请人：Sumitomo Chemical Company, Limited

  公开号：EP2199284A1

  公开（公告）日：2010-06-23

  The present invention provides: a pharmaceutical composition for inhibiting amyloid-β protein accumulation comprising a compound represented by the formulas including (I) or a pharmaceutically acceptable salt thereof; a method for inhibiting amyloid-β protein accumulation, comprising a step of administering an effective amount of the compound represented by the formulas including (I) or a pharmaceutically acceptable salt thereof to a mammal which may be diagnosed with an amyloid-β protein-related disease; and so on.

  本发明提供了：一种用于抑制淀粉样蛋白-β蛋白积累的药物组合物，该组合物由包括（I）在内的式子所代表的化合物或其药学上可接受的盐；一种抑制淀粉样蛋白-β蛋白积累的方法，该方法包括向可能被诊断患有淀粉样蛋白-β蛋白相关疾病的哺乳动物施用有效量的包括（I）在内的式子所代表的化合物或其药学上可接受的盐的步骤；等等。
• BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS
  申请人：LIGAND PHARMACEUTICALS INCORPORATED

  公开号：EP1212303A2

  公开（公告）日：2002-06-12
• JP2003508387A
  申请人：——

  公开号：JP2003508387A

  公开（公告）日：2003-03-04
• PHARMACEUTICAL COMPOSITION FOR INHIBITING AMYLOID-beta PROTEIN ACCUMULATION
  申请人：Motonaga Kozo

  公开号：US20100204216A1

  公开（公告）日：2010-08-12

  The present invention provides: a pharmaceutical composition for inhibiting amyloid-β protein accumulation comprising a compound represented by the formulas including (I) or a pharmaceutically acceptable salt thereof; a method for inhibiting amyloid-β protein accumulation, comprising a step of administering an effective amount of the compound represented by the formulas including (I) or a pharmaceutically acceptable salt thereof to a mammal which may be diagnosed with an amyloid-β protein-related disease; and so on.